Results 81 to 90 of about 5,788 (178)

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source

Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial

Acta Medica Indonesiana
Background: Patients with chronic kidney disease undergoing hemodialysis are at risk of hepatitis C virus exposure due to nosocomial transmission and the duration of hemodialysis.
Andri Sanityoso Sulaiman, Pringgodigdo Nugroho, Muhammad Begawan Bestari, Afiatin Afiatin, Fardhah Akil, Akhyar Albaar, Hery Djagat Purnomo, Dwi Lestari, Triyanta Yuli Pramana, Agung Susanto, Desti Rachmani, Lawrence Ho Khek-Yu   +11 more
doaj   +4 more sources

Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals

GMS Ophthalmology Cases, 2016
We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema.
Prud’homme, Sylvie, Nevens, Frederik, Casteels, Ingele   +2 more
doaj   +1 more source

Decreased Liver Fibrosis in Patients with Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Coinfection After Treatment with Sofosbuvir/Daclatasvir [PDF]

, 2019
Background: Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) co-infection increases the progression of liver fibrosis to advanced liver disease and death.
Agustanti, Nenny, Jonathan, Andreas, Wisaksana, Rudi   +2 more
core   +1 more source

Evaluation of the effi cacy and safety of the use of asunaprevir in combination with daclatasvir in patients with chronic hepatitis С: a prospective cohort study

Медицинский вестник Юга России, 2017
Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis.
Elena B. Romanova, Yuri M. Ambalov, Dmitry V. Sizyakin, Irina Y. Khomenko, Oleg I. Khomenko, Karina R. Titiryan   +5 more
doaj   +1 more source

Results from univariable and multivariable logistic regression models to identify independent factors correlated with sofosbuvir and daclatasvir treatment failure (n = 184).

, 2021
Results from univariable and multivariable logistic regression models to identify independent factors correlated with sofosbuvir and daclatasvir treatment failure (n = 184).
Kuntjoro Harimurti (10035887), Evy Yunihastuti (428215), Andri Sanityoso Sulaiman (10881067), Rahmat Hariyanto (11268731)   +3 more
core   +1 more source

STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF DACLATASVIR IN PURE AND TABLETS DOSAGE FORMS

, 2017
A sensitive, simple, selective and accurate HPLC method was developed and validated for analysis of antiviral drug Daclatasvir (BMS-790052, DCV) in pure form and in tablet dosage form in the presence of its degradation products.
Hanaa Saleh, Gamal H. Ragab, Mohammed A. Othman
core   +1 more source

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR [PDF]

, 2017
The purpose of the review is to evaluate the efficacy and safety of using pangenotypic combination «of Sofosbuvir/Daclatasvir» — the direct action antiviral drugs in the treatment of chronic HCV infection at different stages of liver damage.Main ...
M. C. SEMENISTAYA, N. V. SHULPEKOVA, A. A. USANOVA, Y. O. SHULPEKOVA, C. S. PAVLOV   +4 more
core   +1 more source

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj